XELJANZ
- Product NDC
- 63539-029
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- tofacitinib
- Dosage form
- SOLUTION
- Route
- ORAL
- Labeler
- U.S. Pharmaceuticals
- Application
- NDA213082
- Marketing category
- NDA
- Substance
- TOFACITINIB CITRATE
- Current FDA listing
- Yes
Packages
| Package NDC | Description | Marketing start | Marketing end | Sample | Status |
|---|
| 63539-029-02 | 1 BOTTLE in 1 CARTON (63539-029-02) / 240 mL in 1 BOTTLE (63539-029-01) | 2021-02-08 | | No | Historical |
Related DailyMed Labels
| Title | Manufacturer | Effective date | Type | Version |
|---|
| XELJANZ | U.S. Pharmaceuticals | Pfizer Inc | Viatris Pharmaceuticals LLC | Pfizer Ireland Pharmaceuticals Unlimited Company | Pfizer Manufacturing Deutschland GmbH | Pfizer Asia Manufacturing Pte Ltd | Pharmacia & Upjohn Company LLC | 2026-03-27 | HUMAN PRESCRIPTION DRUG LABEL | 17 |
| XELJANZ | U.S. Pharmaceuticals | Pfizer Inc | Viatris Pharmaceuticals LLC | Pfizer Ireland Pharmaceuticals Unlimited Company | Pfizer Manufacturing Deutschland GmbH | Pfizer Asia Manufacturing Pte Ltd | 2025-03-06 | HUMAN PRESCRIPTION DRUG LABEL | 13 |